<DOC>
	<DOCNO>NCT02618798</DOCNO>
	<brief_summary>Background : Thrombosis may crucial drive progression fibrosis chronic liver disease ( CLD ) . The potential role platelet platelet activation process unclear . Platelets participate inflammation secretion pro-inflammatory mediator may advance hepatic fibrosis . Hepatitis B virus transgenic mouse , develop significantly small necroinflammatory focus serum ALT level 80 % low , pre-treated anti-platelet antibody . Sinusoidal aggregation activate platelet also occur chronic hepatitis C human . It may contribute thrombocytopenia observe CLD . Platelet activation generally believe compromise CLD . However , data suggest CLD may even associate enhancement platelet activation . Measurement hepatic venous pressure gradient ( HVPG ) constitute common method estimation portal venous pressure . HVPG significantly correlate histological index CLD progression . Study hypotheses : 1 . HVPG marker advancement hepatic fibrosis progression CLD associate increase platelet activation . 2 . Platelet activation function generally compromise CLD . Comparison platelet function CLD control group healthy volunteer intend clarify whether CLD lead manifest platelet dysfunction Methods : Study design observational . 100 patient CLD various origin ( viral , alcoholic , cholestatic ) schedule routine HVPG measurement enrol . 30 healthy volunteer donate blood control group . Platelet function activation evaluate multiple electrode aggregometry ( primary outcome variable area curve ( AUC ) . Plasma level P-selectin ( ELISA ) , PFA ( Platelet Function Analyzer ) 100™ parameter ( EPI-CT ADP-CT ) , percentage P-selectin , GPIIb/IIIa , thrombin receptor positive platelet stimulation ( flow-cytometry ) constitute secondary outcome parameter . Plasmatic coagulation evaluate rotational thrombelastometry ( ROTEM ) . Platelet count routine coagulation parameter monitor . HVPG measurement hepatic vein catheterization patient blood sample carry via internal jugular vein . Blood sample volunteer perform via antecubital vein Study Rationale : If high level platelet activation associate increase HVPGs , would provide insight pathogenesis CLD . It would also point toward possible benefit anti-platelet therapy CLD . Verification platelet dysfunction CLD relevant clinical practice anaesthesiology intensive care procedure often postpone CLD-patients fear bleeding complication . CLD patient may also receive prophylactic platelet concentrate prior intervention costly , fraught risk bacterial infection may unnecessary absence platelet dysfunction .</brief_summary>
	<brief_title>Hepatic Venous Pressure Gradient Platelet Activation Chronic Liver Disease</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Confirmed chronic liver disease ( CLD ) , alcoholic , viral , cholestatic . CHILDPUGH Stage A , B , C , noncirrhotics Planned routine measurement HVPG . Age : 19 year old Impaired kidney function ( Creatinine &gt; 1.3mg/dl ) Platelet count &lt; 50,000/µl Participation clinical trial 3 week precede study IFNtherapy within 6 month inclusion study . Use antithrombotic anticoagualant medication Pregnancy Intra extrahepatic malignancy Haemostatic diseases cirrhosis Current abuse alcohol ( Abstinence alcohol least 6 week precede study require )</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>chronic liver disease</keyword>
	<keyword>CLD</keyword>
	<keyword>platelet function</keyword>
</DOC>